Cristina Álvarez Escolá-rekin lankidetzan egindako argitalpenak (8)

2019

  1. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma

    Theranostics, Vol. 9, Núm. 17, pp. 4946-4958

2017

  1. PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics

    Journal of Molecular Diagnostics, Vol. 19, Núm. 4, pp. 575-588

2015

  1. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients

    Journal of Medical Genetics, Vol. 52, Núm. 10, pp. 647-656

  2. Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations

    International Journal of Cancer, Vol. 137, Núm. 8, pp. 1870-1878

2013

  1. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions

    American Journal of Pathology, Vol. 182, Núm. 2, pp. 350-362

  2. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma

    Endocrine-Related Cancer, Vol. 20, Núm. 4, pp. 611-619

  3. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways

    Endocrine-Related Cancer, Vol. 20, Núm. 4, pp. 477-493

  4. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis

    Human Molecular Genetics, Vol. 22, Núm. 11, pp. 2169-2176